Next Article in Journal / Special Issue
The Roles of Platelet-Activating Factor and Magnesium in Pathophysiology of Hypertension, Atherogenesis, Cardiovascular Disease, Stroke and Aging
Previous Article in Journal
Cardiovascular Characteristics of Patients with Genetic Variation in Desmoplakin (DSP)
Previous Article in Special Issue
Nanoparticle-Based Modification of the DNA Methylome: A Therapeutic Tool for Atherosclerosis?
Review

An Overview of Therapy Guidelines for Cardiac Arrest and the Potential Benefits of Hemoglobin-Based Oxygen Carriers

1
The Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
2
Department of Basic and Clinical Sciences, TOURO College of Osteopathic Medicine, Middletown, NY 10940, USA
3
OXYVITA Inc., Middletown, NY 10940, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Carla Giustetto
Cardiogenetics 2022, 12(1), 37-48; https://doi.org/10.3390/cardiogenetics12010004
Received: 13 October 2021 / Revised: 8 January 2022 / Accepted: 17 January 2022 / Published: 20 January 2022
(This article belongs to the Special Issue Cardiogenetics: Feature Papers 2021)
Currently, there is an unmet therapeutic need for the medical management of cardiac arrest, as is evident from the high mortality rate associated with this condition. These dire outcomes can be attributed to the severe nature and poor prognosis of this disorder. However, the current treatment modalities, while helping to augment survival, are limited and do not offer adequate improvements to outcomes. Treatment modalities are particularly lacking when considering the underlying pathophysiology of the metabolic phase of cardiac arrest. In this study, we explore the three phases of cardiac arrest and assess the factors related to positive clinical outcomes and survival for these events. Furthermore, we evaluate the present guidelines for resuscitation and recovery, the issues related to ischemia and tissue reperfusion, and the benefit of oxygen-delivery therapeutic methods including blood transfusion therapy and synthetic hemoglobins (HBOCs). The current therapy protocols are limited specifically by the lack of an efficient method of oxygen delivery to address the metabolic phase of cardiac arrest. In this article, we investigate the next generation of HBOCs and review their properties that make them attractive for their potential application in the treatment of cardiac arrest. These products may be a viable solution to address complications associated with ischemia, reperfusion injury, and organ damage. View Full-Text
Keywords: cardiac arrest; tissue reperfusion; cardiac resuscitation; oxygen delivery; hemoglobin-based oxygen carriers (HBOCs) cardiac arrest; tissue reperfusion; cardiac resuscitation; oxygen delivery; hemoglobin-based oxygen carriers (HBOCs)
MDPI and ACS Style

Wollocko, B.M.; Papian-Gorji, B.; Yen, W.; Zahid, U.; Shah, N.; Steier, K.; Wollocko, H. An Overview of Therapy Guidelines for Cardiac Arrest and the Potential Benefits of Hemoglobin-Based Oxygen Carriers. Cardiogenetics 2022, 12, 37-48. https://doi.org/10.3390/cardiogenetics12010004

AMA Style

Wollocko BM, Papian-Gorji B, Yen W, Zahid U, Shah N, Steier K, Wollocko H. An Overview of Therapy Guidelines for Cardiac Arrest and the Potential Benefits of Hemoglobin-Based Oxygen Carriers. Cardiogenetics. 2022; 12(1):37-48. https://doi.org/10.3390/cardiogenetics12010004

Chicago/Turabian Style

Wollocko, Brian M., Bardia Papian-Gorji, Winston Yen, Urooj Zahid, Nilank Shah, Kenneth Steier, and Hanna Wollocko. 2022. "An Overview of Therapy Guidelines for Cardiac Arrest and the Potential Benefits of Hemoglobin-Based Oxygen Carriers" Cardiogenetics 12, no. 1: 37-48. https://doi.org/10.3390/cardiogenetics12010004

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop